Nasal Drug Delivery

This conference gives a comprehensive review within the field of nasal drug delivery while reviewing the very latest new data and innovative technologies.

11-12 Apr 2019

GBP 1,499
EUR 2,099
USD 2,338

Book now

Conference overview

What makes nasal delivery systems more challenging than solid dosage forms? How safe is nasal drug delivery? Are there such things as safe excipients? How does all this fit within the regulatory environment in Europe and the USA? How difficult is it to bring all these products to market?

This seminar seeks to explore these and other questions within the field of nasal drug delivery while reviewing interesting new data, innovative technologies and the very latest scientific developments. Leading authorities in nasal drug delivery will cover relevant aspects of nasal physiology, anatomy, absorption of a variety of drugs in various phases of drug development, and new drugs entering the market. In addition, nasal delivery to the sinuses will be discussed and the programme will include interesting case histories.

This seminar will offer an excellent networking opportunity to build business relationships and discuss all these issues with an unrivalled panel of experts in this field of drug delivery.

Media Partner


Newly updated programme for 2019 below – book your place !

Who should attend?

  • Managing directors
  • Medical directors
  • Heads of regulatory affairs
  • Quality assurance managers
  • Senior executives in research and development
  • Registration associates
  • Marketing managers
  • All departments that are involved in nasal drug delivery, or who wish to understand the potential of this alternative therapeutic route

Those already involved in nasal drug delivery will benefit from updating their knowledge and sharing experiences with some of the leading practitioners in this field. If you are involved in nasal drug delivery or are just considering the potential, this seminar is an excellent route to understanding all aspects from the basic physiology through to launching a successful product.

Three reasons to attend

1. Gain an update on the very latest scientific developments and technology advances in this field.
2. Hear from an unrivalled panel of expert speakers.
3. An excellent networking opportunity to build business relationships.

Programme day one

Nasal drugs to treat nasal disorders: a comprehensive review

  • Anatomy and physiology
  • Nasal disorders
  • Treatment options and future prospects to treat allergic and non-allergic rhinitis
  • CRS with and without nasal polyps
    Professor Valerie Lund

Discussion session

Nasal drug delivery challenges

  • Discuss ideal attributes of a nasal spray formulation
  • Present strategies to optimise deposition
  • Highlight excipients to facilitate absorption
  • Present technology for delivery and formulation characterisation
    Dr Julie Suman

Nasal formulation of drugs

  • Formulation aspects of liquid systems
  • Carrier-based and matrix dry powder formulations for nasal delivery
  • (Nano)particulate drug carriers for nasal administration
  • Interplay of therapeutic targets and nasal deposition
    Dr Regina Scherliess

Discussion session

Developing next generation powder nasal delivery using POD technology

  • Device development efforts
  • Formulation development efforts
  • Unique challenges to powder delivery
    Christopher Fuller

Rethinking nasal packaging environment

  • Using integrated three-phase activ-polymer to control moisture ingress
  • Extend shelf life
  • Improve performance
    Lee Lucas

Discussion session

Key insights for a successful device development to achieve nasal bioequivalence requirements

  • Design and testing techniques for nasal spray devices
  • In-Vitro BioEquivalence (IVBE) requirements and region-specific regulatory strategies
  • Statistical tools and new alternative approach applied to nasal sprays
  • Key success factors for nasal spray development projects
    Pascale Farjas and Céline Petitcola

The unique challenges of nasal drug delivery to treat chronic rhinosinusitis (CRS); considerations before and after sinus surgery

  • Medical therapy in CRS – goals and challenges
  • Endoscopic sinus surgery – implications for drug deposition
  • Nasal delivery methods – advantages and limitations
    Per Djupesland

Programme day two

Review of day one
Dr Julie Suman and Dr René Bommer

Review of nasal drug delivery devices

  • Trends in nasal delivery systems
  • Advances in device technologies
  • Nasal spray characteristics
    Dr René Bommer

Requirements concerning bioequivalence of nasal drug products from an authority’s point of view

  • Bioequivalence of nasal products
  • The evaluation of the monograph for nasal products in the European Pharmacopoeia will be outlined
    Dr Cornelia Nopitsch-Mai

Discussion session

Regulatory science associated with BE/TE for nasal products

  • Average BE versus population BE
  • End point right, outcome wrong: why?
  • Getting the sample size right
  • Lessons learned from inhaled aerosol products
    Anders Fuglsang

US/FDA regulatory guidance on combination products

  • Origin and objective of the regulations
  • The regulation and guidance documents
  • Requirements and expectations of FDA
    Andrew Wood

Discussion session

Qualification of new nasal drug delivery systems for existing drugs

  • Formulation analysis
  • System and compatibility
  • Stability testing
  • Performance testing
  • Production line and efficiency optimisation
    Thomas Grinnan

Investigations regarding the developability of nasal metered dose inhalers

  • Findings
  • Opportunities
    Dr Jag Shur

What are chemisimilars and what’s the problem?

  • Standardisation
  • EU guidance
  • FDA guidance
  • Assay sensitivity and the best models to test for similarity
    Dr John Warren

Discussion session

Concluding remarks

Close of conference and refreshments


John Warren

John Warren is a clinical scientist who established Medicines Assessment Ltd as a pharmaceutical consultancy in 2011 (
He advises multiple pharmaceutical companies on clinical development. He trained in medicine at Guy’s Hospital, where he wrote a thesis on the human physiology of epinephrine. He worked for the UK Medicines Healthcare products Regulatory Agency (MHRA) as an Expert Medical Assessor from 1995-2010 evaluating new drug applications for Europe across the therapeutic spectrum. He was a member of the European Scientific Advice Working Party 2003-2010; Pharmacokinetic Subgroup of the Efficacy Working Party 2007-2008. He contributed to the EU Notes for Guidance on Asthma, COPD, ARDS and Bioequivalence. When appointed to the MHRA in 1995 he took a concomitant Honorary Senior Lectureship in Clinical Pharmacology at St Thomas’ Hospital.

Previously a Senior Lecturer at the National Heart and Lung Institute, with Honorary Consultant status at the Brompton, Charing Cross and Chelsea & Westminster Hospitals, 1990-1994. This followed a Senior Registrar post in Clinical Pharmacology at the Royal Postgraduate Medical School 1986-1990.
Specialist UK accreditation was granted in General Medicine, Clinical Pharmacology and Cardiology. He is the author of over 100 publications on pharmacology and a book on the Endothelium.

Guest speaker at the 2010 Annual Austrian Pharmacological Society meeting. British Pharmacology Society Guest Lecturer at the 2013 Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists. Guest speaker at Inhalation Drug Delivery Association 2016 Conference, China. For a review of drug development please see “Drug Discovery: Lessons from Evolution” BJCP 2011;71:497-503. Previously a Member of the Editorial Board of Clinical Pharmacology & Therapeutics and Microvascular Research. Currently Executive Editor for British J Clinical Pharmacology and member of the Joint Speciality Committee for Clinical Pharmacology of the Royal College of Physicians, London. Member of the research committee for the Cure Parkinson’s Trust.

Valerie Lund

Valerie Lund is Professor Emeritus of Rhinology at the Ear Institute, University College London and is an Honorary Consultant ENT Surgeon at the Royal National Throat Nose and Ear Hospital (University College London Trust), University College Hospital. She deals with all nose and sinus conditions with a particular interest in sinonasal tumours and has been involved in endoscopic sinus surgery and its extended applications since the early 1980’s. She has contributed extensively to the literature with 36 books and monographs, 86 chapters and over 320 peer-reviewed papers and has lectured widely, delivering 19 eponymous lectures, including the Semon, Stirk Adams, Stell and Wilde lectures in the last 5 years.

She has received several prizes including the George Davey Howell (1990, 2008, 2015), W J Harrison (Royal Society of Medicine 2012), BMA Book awards and Jobson Horne Prize (2018). She is the only non-American editor of ‘Cummings Otorhinolaryngology’ and her most recent book, ‘Tumors of the Nose, Paranasal Sinuses and Nasopharynx’ was published by Thieme in April 2014.

Rene Bommer

Dr. René Bommer is a founder and an owner of pharmAccel Consulting.
He received his Ph.D. in Chemistry from the University of Constance in Germany in 1990. After research positions at the Scripps Clinic in San Diego, USA , at Altana Pharma Germany (now Takeda) and a lectureship at the University of Buenos Aires he joined the device developing and manufacturing company Ing. Erich Pfeiffer GmbH in Germany and became a Director of Business Development. In 2007 René founded a consulting company with a focus on delivery devices. pharmAccel Consulting delivers a service to support an accelerated entry into the market with consideration of technical, regulatory, marketing and pharmaeconomical aspects of the drug delivery device business.

Per Gisle Djupesland

Per G Djupesland, M.D., Ph.D. is the inventor of OptiNose’s patented, Breath Powered™ Bi-Directional™ nasal drug delivery technology. He has been Chief Scientific Officer of OptiNose since 2000 and is in charge of scientific efforts at OptiNose.
Dr. Djupesland is an Otorhinolaryngologist with a specialization in rhinology and more than 25 years of clinical experience in infectious diseases, epidemiology and surgery.
He has been Clinical Research Fellow at the Hospital for Sick Children and Toronto General in Toronto, Canada, primarily studying the role of Nitric Oxide in the upper airways.
He also authored more than 50 peer reviewed articles in international medical journals, and filed 35 patent families/patent applications.

Julie Suman

Dr. Julie D. Suman, R.Ph., Ph.D., is a co-founder and President of Next Breath, LLC, an incubator company located at the UMBC Technology Center. Next Breath, which incorporated in April 2002, is a contract research organisation dedicated to the development of nasal and inhalation delivery systems. She directs the contract research division that supports product development for North American and European clients in the pharmaceutical, biotechnology and medical device markets.

Julie holds a B.S. in Pharmacy from Duquesne University (1996) and a Ph.D. in Pharmaceutical Sciences from the University of Maryland, Baltimore (2002). She is a licensed Maryland pharmacist and a member of the Maryland Pharmacy Volunteer Corp. Julie has also been an affiliate assistant professor in the Department of Pharmaceutics at Virginia Commonwealth University since 2009.

Anders Fuglsang

Anders Fuglsang graduated in 1998 from the Royal Danish School of Pharmacy, Copenhagen, spending part of his studies at Leiden University, Netherlands. He was awarded his PhD in 2002 specialising in cardiovascular pharmacology. Following work as an Assistant Professor, he worked as a consultant for a number of Originator Pharmaceutical companies at a brand optimisation company in Copenhagen.

In 2005, he joined the Norwegian Medicines Agency as a Clinical Assessor and became Expert Advisor to the WHO and member of the Efficacy Working Party at the EM(E)A. He was Chair of the sub-group for Orally Inhaled Products and was also a member of the PK-subgroup. Other duties included provision of Expert Scientific Advice, GCP-inspection and -training, and responsibility for Assessor Training at the EM(E)A.

Through 2009 to September 2010, he was Clinical and Regulatory Strategy Manager at a world leading generic company. He has now established his own pharmaceutical consultancy. Clients include the World Health Organization, generic companies, innovators, drug delivery firms and investment banks.
He is the author of approximately 30 papers in the fields of Generics, Genetics and Pharmacology, and is a reviewer for some 15+ international journals including Science, Trends in Genetics and Drug Discovery Today.

Jag Shur

Jag Shur began his career with Profile Drug Delivery where he was developing inhalation drug delivery systems for cystic fibrosis patients.He then went on to work for GlaxoSmithKline, following which he completed his PhD entitled “Formulated Muco-Regulatory Agents in the Airways of Patients with Cystic Fibrosis” at Portsmouth School of Pharmacy.

Jag is currently a research fellow at the University of Bath where he is investigating bioequivalence of inhaled products.

Pascale Farjas

Pascale Farjas is a Global Category Manager for the ENT (ear, nose, and throat) segment at Nemera, a leading developer and manufacturer of healthcare packaging and devices. Her role encompasses understanding patients’ needs and regulatory requirements to develop and market packaging solutions that improve the patient experience. She is also in charge of the market introduction of new pump platforms for nasal sprays.

Prior to joining Nemera, Pascale held various positions in strategic market intelligence and operational marketing for international markets in the pharmaceutical industry.
Pascale holds a degree in chemical engineering from the National Institute of Applied Sciences of Rouen in France. She also earned a marketing-focused Master Degree from the Business Administration Institute (France).

Regina Scherließ

Prof. Dr. Regina Scherließ (*1979) is a professor for Pharmaceutics and Biopharmaceutics, director of the section Pharmacy and chair of the Department of Pharmaceutics at Kiel University, Germany. As such she leads the research unit in Pharmaceutics and is responsible for all teaching in Pharmaceutics and Biopharmaceutics at Kiel University. She is a pharmacist and received her Dr. rer. nat. (doctor of natural sciences) in 2008 for a work on “Formulation of inhalation combination products by co-precipitation”. In 2015 she finished her “habilitation” working on “Mucosal vaccination via the respiratory tract”. During her academic education she had research stays in Denmark, the US, New Zealand and Australia. She also received several young researcher awards including The Pat Burnell New Investigator Award 2010 of the Aerosol Society and is member of the DDL scientific committee (since 2015). Her research interests include disperse systems and nanoparticles, stabilization of biomolecules in spray drying and formulations for mucosal vaccination with a focus on respiratory (nasal and pulmonary) dry powder delivery.

Tom Grinnan

Thomas Grinnan, Vice President, Sales & Marketing, Healthcare, Silgan Dispensing Systems, has worked in the pharmaceutical industry for more than 28 years as an executive, innovator, consultant and business development specialist. A biologist, he began his career in the Healthcare practice of Markowitz & McNaughton, Inc., a strategy consulting firm, working closely with pharmaceutical and medical device companies. After receiving his MBA, he began a long career with Mebane Packaging, a healthcare packaging company, and its antecedents Westvaco and MeadWestvaco.

At MeadWestvaco, Tom held various leadership roles in the Patient Adherence and Healthcare Packaging business, leading European sales & marketing, global clinical trial packaging, as well as business development and innovation. After MeadWestvaco (subsequently renamed Westrock), Tom joined Silgan Dispensing Systems, aspin-off specializing in the supply of pump and liquid dispensing solutions. Silgan DispensingSystems is a leading partner to the pharmaceutical industry, supplying pumps and dispensing systems for nasal, ophthalmic, topical, oral and otic applications. Tom received his BA fromthe University of Virginia and his MBA from the University of North Carolina, Chapel Hill.

Lee Lucas

Lee Lucas is Vice President of Applications and Business Development, Aptar CSP Technologies. He has over 25 years of project management and manufacturing experience. Lee has spent the last 8 years with Aptar CSP Technologies developing custom product solutions using its material science technology going from concept to commercialization into both domestic and international markets. His responsibilities include R&D, regulatory, design and development for both the US and France locations. Prior to joining CSP, he spent 10 year of his career as a General Manager directing large CMO plants producing aerosol, liquids, creams in the personal beauty, pharmaceutical and home care market segments. He has a bachelor of science in mechanical engineering and is a six-sigma black belt.

Céline Petitcolas

Céline Petitcolas holds Materials engineer degree from the National School of Chemic and Physic of Bordeaux (France). Her current position is Customer Technical Support for nasal range at Nemera. Following a first R&D experience in automotive industry, Céline joined Nemera in 2012 to develop pharmaceutical device and especially for nasal spray area. Her new role consists in helping and assisting customers from a technical point of view in their development for nasal spray and more specifically on Bioequivalence topics.

Andrew Wood

Andrew Wood, Associate Director Regulatory Affairs, Aptar Pharma. Originally a graduate in Chemistry, Andrew has worked with Aptar Pharma for 10 years managing their Regulatory Affairs team. Having previously held posts with GlaxoSmithKline and Bespak in technical project management and quality assurance roles, Andrew has amassed more than 30 years experience in development of nasal and inhalation products and drug delivery devices.

Christopher Fuller

Christopher Fuller, Associate Director of Engineering, Impel NeuroPharma. Christopher has worked at Impel since 2012, developing Impel’s patented POD technology. He has a background in physics and applied mathematics completing both graduate and undergraduate work at the University of Washington. His current role is focused on new product introduction, developing and launching Impel assets across Migraine, Parkinson’s Disease, and acute agitation.

Cornelia Nopitsch-Mai

Dr Cornelia Nopitsch-Mai studied pharmacy at the Free University Berlin and graduated in pharmaceutical biology. She is scientist at the Federal Institute for Drugs and Medical Devices in the assessment of the quality of the dossier since 1991.

She is experienced in the assessment of pharmaceutical dossiers for marketing authorisation applications of medicinal products. She has broad knowledge of the national and EU regulations medicinal products as well as for the corresponding EU guidelines and the European Pharmacopoeia. Since 2000 she is assessor for the Certification Procedure (EDQM) in Strasbourg. She was member of the Technical Advisory Board (TAB) from 2001 to 2010. She was chairperson of the TAB from 2005 to 2010. She was member of the Quality Working Party from October 2007 to February 2011. Since 2014 she is member of the INH Working Party.

Book now

11-12 Apr 2019
11-12 Apr 2019 Holiday Inn London - Kensington Forum, London GBP 1,499.00
EUR 2,099.00
USD 2,338.00
+ VAT @ 20.00%
Enrol now

You may also be interested in

Previous customers include...

  • Actelion Pharmaceutical Ltd
  • Auris Medical AG
  • BD
  • Bespak Europe Ltd
  • ChemImage Corporation
  • Danish University of Pharmaceutical Sciences
  • Interdos Pharma bv
  • J Uriach Y Compania
  • Jenson R+ Ltd
  • Malvern Instruments Ltd
  • Next Breath LLC
  • Nolato Medical Business Area
  • OnDrugDelivery Ltd
  • Pharmacosmos A/S
  • Proveris Scientific Corporation
  • Rexam Healthcare La Verpilliere
  • Sagentia Limited
  • SiO2 Medical Products
  • Spital - Pharmazie
  • Takeda GmbH
  • Vertex
  • Vertex Pharmaceuticals
  • Zambon Group SpA
  • Zentiva Group AS

Well organised, good agenda!

Michiharu Kageyama, Manager, Teijin Pharma Limited

Very well organised, good speakers.

Ana Campo Rodrigo, Postdoctoral Research Fellow, University of York

The speakers were all very well spoken and gave a good overview of the background to their research/product before going into detail. It was a very well organised programme with a variety of interesting topics delivered by experts within the field.

Gillian Hutcheon, Reader, Liverpool John Moores University

A great collection of knowledgable speakers

Matthew Burton, , Jenson R+ Ltd


Nicola Hardman, , Jenson R+ Ltd